KR20180029317A - Composition for preventing, improving or treating liver damage - Google Patents
Composition for preventing, improving or treating liver damage Download PDFInfo
- Publication number
- KR20180029317A KR20180029317A KR1020160117009A KR20160117009A KR20180029317A KR 20180029317 A KR20180029317 A KR 20180029317A KR 1020160117009 A KR1020160117009 A KR 1020160117009A KR 20160117009 A KR20160117009 A KR 20160117009A KR 20180029317 A KR20180029317 A KR 20180029317A
- Authority
- KR
- South Korea
- Prior art keywords
- liver
- bile
- composition
- nitalia
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 206010067125 Liver injury Diseases 0.000 title abstract description 22
- 231100000234 hepatic damage Toxicity 0.000 title abstract description 18
- 230000008818 liver damage Effects 0.000 title abstract description 18
- 210000000941 bile Anatomy 0.000 claims abstract description 65
- 208000019423 liver disease Diseases 0.000 claims abstract description 33
- 210000004185 liver Anatomy 0.000 claims abstract description 16
- 208000006454 hepatitis Diseases 0.000 claims description 16
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 4
- 231100000354 acute hepatitis Toxicity 0.000 claims description 4
- 206010023126 Jaundice Diseases 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 201000008865 drug-induced hepatitis Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000003908 liver function Effects 0.000 abstract description 8
- 241000700110 Myocastor coypus Species 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 7
- 239000013642 negative control Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 10
- 210000000232 gallbladder Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012333 histopathological diagnosis Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- Y10S514/893—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 간 기능 개선, 간 손상 억제 및 간질환 치료에 효과적인 간손상 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating liver damage, which is effective for improving liver function, suppressing liver damage and treating liver disease.
간은 영양소 대사의 중심 역할을 하는 장기로 정상적인 사람의 간은 약 1,500g의 무게를 가지며 간 기능의 이상이 초래되면 생체의 영양소 대사에 문제를 유발하여, 포도당을 글리코겐으로 만들거나 또는 단백질을 알부민으로 전환하거나 불필요한 것을 분해하여 쓸개즙으로 전달하는 등의 간의 기능에 이상이 생긴다. 정신적 휴식을 가질 경우 경미한 간 손상의 경우, 간세포는 다시 복구 될 수 있지만, 바쁜 현대사회에서는 휴식을 취할 여유를 가질 수 없어서 간질환이 가중되기도 한다. 일반적으로 간에 염증이 생기는 간염이 간질환의 대부분을 차지하며, 양상에 따라 급성 간염과 만성 간염, 원인에 따라 바이러스성 간염, 알코올성 간염, 약물성 간염 등으로 나눌 수 있다. 이런 이상으로 유발되는 간질환에는 지방간, 간염, 간경변증, 간암 등이 있다. 운동이나 금주, 식이요법 등과 약물 치료 등을 병행해서 간질환을 치료하고는 있지만, 근본적으로 완전히 치유가 되기는 어렵기 때문에 효과적이고 개선된 간질환 치료제 또는 보호제의 개발이 계속적으로 필요하다.The liver plays a central role in nutrient metabolism. Normal human liver weighs about 1,500 g. If liver function abnormality is caused, it causes problems in the metabolism of nutrients in the living body. Thus, glucose is made into glycogen, Or transferring unnecessary parts to the bile, resulting in abnormal liver function. In the case of mild liver damage with mental breakdown, hepatocytes can be restored again, but in modern, busy societies, liver disease can be overloaded because they can not afford to rest. Generally, hepatitis, which causes inflammation of the liver, accounts for most of the liver diseases, and it can be divided into acute hepatitis and chronic hepatitis according to the pattern, viral hepatitis, alcoholic hepatitis and drug-induced hepatitis according to the cause. Liver abnormalities caused by these abnormalities include fatty liver, hepatitis, liver cirrhosis and liver cancer. Although the liver disease is treated in conjunction with exercise, diet, and medication, it is difficult to completely heal, so it is necessary to develop an effective and improved liver disease treatment or protection agent.
간 손상의 원인은 산화스트레스에 의한 항산화계 효소 공급원의 고갈과 간 손상에 대항할 수 있는 간세포의 기능 저하가 주요 원인으로 알려져 있다. 또한 간세포의 사멸은 거의 모든 종류의 인간의 간 손상에 관여하며, 바이러스, 세균 감염, 독성물질의 노출, 대사기능이상, 자가 면역반응 등으로 유도된 간 손상에서부터 급성 및 만성의 간질환의 검출을 위한 중요한 변수이다. 많은 임상연구들과 동물 실험모델들은 간세포의 사멸이 염증에서부터 간 섬유화, 간경변, 간암에 이르기까지의 과정을 매개하는 전형적인 간질환 발달의 중요 요소라고 보고하였다.The cause of liver damage is known to be caused by depletion of antioxidant enzyme source due to oxidative stress and decreased function of hepatocytes against liver damage. In addition, the death of hepatocytes is involved in nearly all kinds of human liver damage and is associated with liver damage induced by viruses, bacterial infections, exposure of toxic substances, metabolic dysfunction, autoimmune reactions, and detection of acute and chronic liver disease . Many clinical studies and animal models have reported that hepatocyte apoptosis is an important factor in the development of typical liver disease that mediates the process from inflammation to hepatic fibrosis, cirrhosis and liver cancer.
간은 체내로 들어온 내독소의 제거에 주로 작용하는 장기이므로 내독소의 체내 침투는 간 손상을 일으킨다. 또한, 간은 알코올 대사의 주요 기관으로써, 알코올은 섭취 후 간에서 알코올 탈수소효소, CYP 2E1 효소 및 카탈라아제(catalase)에 의하여 아세트알데히드(acetaldehyde)로 전환된다. 알코올의 과다 섭취는 과량의 아세트알데히드 생성을 일으켜 글루타치온(glutathione, GSH)과 같은 산화스트레스를 줄여주는 항산화 물질을 저해하여 간 손상을 유발하며, 간경화, 간경변 및 간섬유증과 같은 알코올성 간 질환의 위험성을 증가시킨다. Since the liver is the organs that act mainly in the removal of endotoxins entering the body, penetration of endotoxins into the body causes liver damage. In addition, liver is the main organ of alcohol metabolism. Alcohol is converted to acetaldehyde by alcohol dehydrogenase, CYP2E1 enzyme and catalase in the liver after ingestion. Excessive intake of alcohol causes excessive acetaldehyde production, inhibiting antioxidants that reduce oxidative stress such as glutathione (GSH), leading to liver damage, and the risk of alcoholic liver disease such as cirrhosis, cirrhosis and liver fibrosis .
만성적인 간 손상은 해독 및 방어 작용을 가진 간의 기능을 상실할 때까지 자각하지 못하는 경우가 대부분이며 간질환의 주요 원인이 되고 있다. 간염 및 간경화의 치료와 간 기능 개선을 위해 인터페론, 우르소데옥시콜린산, 실리마린, 비타민 B 등이 사용되고 있다.Chronic liver damage is often the cause of liver disease, which is often not understood until liver function with detoxification and defenses is lost. Interferon, ursodeoxycholic acid, silymarin, and vitamin B have been used to treat hepatitis and cirrhosis and to improve liver function.
본 발명은 뉴트리아 담즙을 유효성분으로 포함하여 부작용 없이 우수한 간 기능 개선, 간 손상 억제 및 간질환 치료 효과를 나타낼 수 있는 간보호 또는 간질환 예방, 개선 또는 치료용 조성물을 제공하는 것을 목적으로 한다.It is intended to provide a composition for prevention or improvement or treatment of liver disease or liver disease which can exhibit excellent liver function improvement, liver damage inhibition and therapeutic effect of liver disease without side effects by containing nitalia bile as an active ingredient.
또한 본 발명은 간 보호 또는 간질환의 예방, 개선 또는 치료 효과를 가지는 약학 또는 식품 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a pharmaceutical or food composition having the effect of preventing, ameliorating or treating liver diseases or liver diseases.
상기 목적을 달성하기 위하여, 본 발명은 뉴트리아 담즙을 유효성분으로 포함하는 간질환 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating liver disease comprising nitalia bile as an active ingredient.
상기 뉴트리아 담즙은 조성물 총 100중량부에 대하여 0.01~95중량부로 포함되는 것이 바람직하다.It is preferable that the nitalia bile is contained in an amount of 0.01 to 95 parts by weight based on 100 parts by weight of the total composition.
상기 간질환은 급성간염, 만성간염, 지방간증, 간경화증, 간섬유화증, 간암, 약물에 의한 간염, 황달, 간경화 등일 수 있다.The liver disease may be acute hepatitis, chronic hepatitis, lipid hepatitis, liver cirrhosis, liver fibrosis, liver cancer, hepatitis due to drug, jaundice, cirrhosis and the like.
또한, 본 발명은 뉴트리아 담즙을 유효성분으로 포함하는 간 보호 및 간 질환의 예방 또는 개선용 식품 조성물을 제공한다.The present invention also provides a food composition for preventing or ameliorating liver diseases and liver diseases comprising nitalia bile as an active ingredient.
본 발명에 따르면 뉴트리아 담즙을 유효성분으로 포함하여 웅담 대용품으로 활용하여 부작용 없이 간기능 개선, 간손상 억제, 간질환 예방 및 치료를 위해 사용될 수 있다. According to the present invention, the present invention can be used as an anti-depressant substitute containing Nitalia bile as an active ingredient and can be used for improving liver function, inhibiting liver damage, preventing and treating liver disease without side effects.
도 1은 본 발명의 일실시예에 따라 TAA에 의해 간손상이 유도된 마우스의 담즙 투여에 따른 체중 변화를 나타낸 도이다.
도 2는 발명의 일실시예에 따라 TAA에 의해 간손상이 유도된 마우스의 담즙 투여에 따른 혈청의 GOT 및 GPT 변화를 나타낸 도이다.
도 3은 발명의 일실시예에 따라 TAA에 의해 간손상이 유도된 마우스의 담즙 투여에 따른 혈청의 TP 및 ALB의 변화를 나타낸 도이다.
도 4는 발명의 일실시예에 따라 TAA에 의해 간손상을 유도한 후 멸균생리식염수를 투여한 마우스와 10㎎/㎏의 담즙희석액을 투여한 마우스의 간 조직에 대한 병리소견을 나타낸 도이다.Brief Description of the Drawings Fig. 1 is a graph showing changes in body weight according to bile administration in mice in which hepatic injury was induced by TAA according to an embodiment of the present invention. Fig.
FIG. 2 is a graph showing changes in GOT and GPT of serum according to bile administration in mice in which hepatic injury was induced by TAA according to an embodiment of the present invention. FIG.
FIG. 3 is a graph showing changes in serum TP and ALB according to biliary administration in mice in which liver injury was induced by TAA according to an embodiment of the present invention.
FIG. 4 is a view showing the pathological findings of liver tissues of a mouse administered with sterile physiological saline after inducing liver damage by TAA according to an embodiment of the present invention and a mouse administered with bile dilution of 10 mg / kg.
이하 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 뉴트리아 담즙을 유효성분으로 포함하는 간 보호 및 간질환 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating liver diseases and liver diseases, which comprises nitalia bile as an active ingredient.
상기 뉴트리아 담즙은 뉴트리아 담낭으로부터 통상의 방법에 따라 분리할 수 있다.The nitalia bile can be isolated from the gall bladder by a conventional method.
상기 뉴트리아 담즙은 건조한 뉴트리아 담낭에서 담즙액을 채취하는 방법, 뉴트리아 생체에서 적출된 즉시의 담낭에서 담즙액을 채취하는 방법, 뉴트리아 생체로부터의 적출없이 담낭에서 직접 담즙액을 채취하는 방법 등으로 채취할 수 있으며, 채취방법은 조금씩 다르다. 예를 들어, 건조한 뉴트리아 담낭의 경우에는 Hagey 등(1993)의 방법에 따라 이소프로판올을 처리하여 박테리아에 의한 변성을 방지한 다음, Nakayama와 Nakagaki(1980)의 방법에 따라 뉴트리아 담낭을 알콜에 넣어 물중탕하여 담즙산을 추출하며, 이 추출물에 테스토스테론(testosteron acetate, 200㎍/mL)을 첨가하는 방법과 수산화나트륨을 처리하는 방법 등으로 채취할 수 있다. The above-mentioned Nitalia bile can be obtained by collecting bile from dry gallbladder of Neutria, collecting bile from gallbladder as soon as it is extracted from the organism of Neutria, collecting bile fluid directly from gallbladder without extracting from Neutria organism And the sampling method is slightly different. For example, in the case of dry neu- tral gallbladder, isopropanol is treated according to the method of Hagey et al. (1993) to prevent bacterial degeneration. Then, according to the method of Nakayama and Nakagaki (1980) , Extracting bile acid, and adding testosterone (200 μg / mL) and sodium hydroxide to the extract.
좀더 구체적으로, 상기 뉴트리아 담즙은 건조된 뉴트리아 담낭에 20배액(w/v)의 에탄올(100%)을 첨가하고 담낭을 절단한 다음, 32~45℃에서 10~15시간 동안 진탕하여 담즙산을 유리한 후, 유리된 담즙산액을 원심분리하여 회수한 상등액을 여과하여 분리할 수 있다. 또한 뉴트리아 담즙은 뉴트리아 담낭을 세절하여 세척한 후 열처리 또는 효소처리하여 뉴트리아 담즙을 분리할 수도 있다.More specifically, the Nitalia bile is prepared by adding 20 times (w / v) ethanol (100%) to a dried neurotic gall bladder, cutting the gallbladder and then shaking at 32 to 45 ° C for 10 to 15 hours, Thereafter, the liberated bile acid solution is centrifuged, and the recovered supernatant can be separated by filtration. In addition, the bile of Nutria may be cleaved by washing the gallbladder of Nutria, and then heat-treated or enzymatically treated to isolate Nutria bile.
상기와 같이 분리한 뉴트리아 담즙은 통상의 방법에 따라 HPLC(high pressure liquid chromatography) 방법에 의해 분석할 수 있다. The nitalia bile thus separated can be analyzed by a high pressure liquid chromatography (HPLC) method according to a conventional method.
상기 간질환은 급성간염, 만성간염, 지방간증, 간경화증, 간섬유화증, 간암, 약물에 의한 간염, 황달, 간경화 등일 수 있다.The liver disease may be acute hepatitis, chronic hepatitis, lipid hepatitis, liver cirrhosis, liver fibrosis, liver cancer, hepatitis due to drug, jaundice, cirrhosis and the like.
이에 본 발명은 뉴트리아 담즙을 유효성분으로 포함하는 간질환 예방 또는 치료용 약학 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for the prevention or treatment of liver disease comprising nitalia bile as an active ingredient.
상기 뉴트리아 담즙은 약학 조성물 총 100중량부에 대하여 0.01~95중량부로 포함되는 것이 바람직하며, 더욱 바람직하게는 1~80중량부로 포함하는 것이다. 그 함량이 0.01중량부 미만일 경우에는 복용 효율성이 떨어질 수 있으며, 95중량부를 초과할 경우에는 제형화에 어려움이 있을 수 있다.The amount of the nitalic bile is preferably 0.01 to 95 parts by weight, more preferably 1 to 80 parts by weight based on 100 parts by weight of the total amount of the pharmaceutical composition. When the content is less than 0.01 part by weight, the efficiency of taking may be lowered, and when it is more than 95 parts by weight, it may be difficult to formulate.
또한, 뉴트리아 담즙은 저농도 투여로도 효과적인 간보호 및 간질환 예방 또는 치료 효과를 갖는다. 뉴트리아 담즙이 100㎎/㎏을 초과하는 농도로 사용될 경우 부작용이 있을 수 있어, 100㎎/㎏ 이하의 농도로 사용되는 것이 바람직하다. Nutrient bile also has effective liver protection and liver disease prevention or treatment effects even at low doses. When the nitalia bile is used at a concentration exceeding 100 mg / kg, side effects may be present, and it is preferable to use it at a concentration of 100 mg / kg or less.
본 발명의 조성물은 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌(Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유 등이 있다. 상기 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카보네이트(calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
본 발명은 약학 조성물은 연구자, 수의사, 의사 또는 기타 임상에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양, 즉 치료되는 질환 또는 장애의 증상의 완화를 유도하는 양인 치료상 유효량으로 투여할 수 있다. 본 발명의 약학 조성물에 대한 치료상 유효 투여량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 바람직한 효과를 위해서, 본 발명의 약학 조성물은 1~10,000㎎/㎏/day, 바람직하게는 1~200㎎/㎏/day의 양으로 투여할 수 있으며, 하루에 한번 투여할 수도 있고, 수 회에 나누어 투여할 수도 있다. The present invention relates to pharmaceutical compositions comprising an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, physician or other clinician, RTI ID = 0.0 > effective < / RTI > amount. It will be apparent to those skilled in the art that the therapeutically effective dose and frequency of administration for the pharmaceutical compositions of the present invention will vary with the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. For a desired effect, the pharmaceutical composition of the present invention may be administered in an amount of 1 to 10,000 mg / kg / day, preferably 1 to 200 mg / kg / day, or may be administered once a day, It may be administered separately.
본 발명의 약학 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical compositions of the present invention can be administered to a subject in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
또한 본 발명의 조성물은 간 보호, 간질환 또는 합병증의 예방 또는 치료를 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 또는 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention can also be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers for the prevention or treatment of liver diseases, liver diseases or complications.
또한 본 발명은 뉴트리아 담즙을 유효성분으로 포함하는 간 보호 및 간 질환의 예방 또는 개선용 식품 조성물을 제공한다. 본 발명의 뉴트리아 담즙이 식품 첨가물로 사용할 경우, 상기 뉴트리아 담즙을 그대로 첨가하거나, 다른 식품 또는 식품 성분과 함께 혼합하여 사용되는 등 통상적인 방법에 따라 적절하게 사용될 수 있다. The present invention also provides a food composition for preventing or ameliorating liver diseases and liver diseases comprising nitalia bile as an active ingredient. When the nitalia bile of the present invention is used as a food additive, it can be suitably used according to a conventional method such as adding the nitalia bile directly or mixing with another food or food ingredient.
또한 상기 유효성분인 뉴트리아 담즙의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 변경될 수 있음은 물론이며, 상기 뉴트리아 담즙은 식품 조성물 총 100중량부에 대하여 0.01~95중량부로 포함되는 것이 바람직하며, 더욱 바람직하게는 1~80중량부로 포함되는 것이다. 그 함량이 0.01중량부 미만일 경우에는 복용 효율성이 떨어질 수 있으며, 95중량부를 초과할 경우에는 제형화에 어려움이 있을 수 있다.The amount of the nitalia bile, which is an effective ingredient, may be suitably changed according to the intended use (prevention, health or therapeutic treatment), and the nitalia bile may be used in an amount of 0.01 to 95 parts by weight per 100 parts by weight of the total food composition , And more preferably 1 to 80 parts by weight. When the content is less than 0.01 part by weight, the efficiency of taking may be lowered, and when it is more than 95 parts by weight, it may be difficult to formulate.
구체적인 예로, 식품 또는 음료의 제조 시에는 본 발명의 감뉴트리아 담즙은 원료에 대하여 15중량% 이하, 바람직하게는 10중량% 이하의 양으로 첨가되는 것이다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하여 장기간 섭취할 경우에는 상기 범위 이하의 양으로 첨가될 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. As a specific example, when producing foods or beverages, the amount of the sensitizing bile bile of the present invention is not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, when it is intended for health and hygiene purposes or for the purpose of controlling health, it can be added in an amount below the above range, and there is no problem in terms of safety. Therefore, the active ingredient can be used in an amount exceeding the above range have.
상기 식품의 종류에는 특별한 제한은 없다. 본 발명의 뉴트리아 담즙류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료, 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. The present invention can be applied to nutritional foods such as Nutria bile, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, .
본 발명의 식품 조성물이 음료로 제조될 경우 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 포함할 수 있다. 상기 천연 탄수화물로는 포도당, 과당 등의 모노사카라이드; 말토오스, 수크로오스 등의 디사카라이드; 덱스트린, 사이클로덱스트린 등의 천연 감미제나 사카린, 아스파르탐 등의 합성 감미제 등이 사용될 수 있다. 상기 천연 탄수화물은 본 발명의 식품 조성물 총 중량에 대하여 0.01~10중량%, 바람직하게는 0.01~0.1중량%로 포함되는 것이다.When the food composition of the present invention is prepared as a beverage, it may contain additional ingredients such as various flavors or natural carbohydrates such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame, and the like. The natural carbohydrate is contained in an amount of 0.01 to 10% by weight, preferably 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 뿐만 아니라, 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 상기의 첨가제 비율은 크게 제한되지는 않으나, 본 발명의 식품 조성물 총 중량에 대하여 0.01~0.1중량% 범위내로 포함되는 것이 좋다. In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , Carbonating agents used in carbonated beverages, and the like. In addition, the compositions of the present invention may include flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of the above additives is not limited to a great extent, but may be in the range of 0.01 to 0.1% by weight based on the total weight of the food composition of the present invention.
이하에서는 실시예를 들어 본 발명에 관하여 더욱 상세하게 설명할 것이나. 이들 실시예는 단지 설명의 목적을 위한 것으로 본 발명의 보호 범위를 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to examples. These embodiments are for purposes of illustration only and are not intended to limit the scope of protection of the present invention.
실시예Example 1. One. 뉴트리아nutria 담즙 채취 Brewing
포획한 뉴트리아를 이산화탄소 가스로 안락사하여 신선 사체를 부검하였다. 개체의 외관 및 내부 장기 상태를 확인한 후 담즙이 들어있는 담낭을 통째로 떼어내거나, 18G 주사바늘 및 100㏄ 이상 주사기를 이용하여 담즙을 채취하였다. 채취한 담낭 및 담즙은 동결건조하여 분말화하여 이후 실험에 사용하였다.Nutrient trapped was euthanized by carbon dioxide gas and autologous autopsy was performed. After confirming the appearance of the individual and the internal organs, the gallbladder containing the bile was totally removed, or bile was collected using a 18G needle and a syringe of 100cc or more. The collected gallbladder and bile were lyophilized and powdered for later use.
실시예Example 2. 2. 간손상Liver damage 마우스의 체중 변화 Weight change in mice
2-1. 실험동물 준비2-1. Preparation of experimental animals
7~8 주령의 수컷 C57BL/6 마우스를 1주간 순화시킨 후 실험에 사용하였다. 각 실험당 정상대조군, 음성대조군 및 실시예 1에서 제조된 4개의 담즙투여군(10, 20, 50, 100㎎/㎏)을 포함한 총 6군을 실험대상군으로 설정하고, 각 실험군 당 3~5마리의 마우스를 사용하였다. 마우스의 간손상을 유도하기 위해 1주간 순화시킨 각각의 마우스에 멸균생리식염수에 녹인 TAA(thioacetamide, 분자량;75.1, 화학식; C2H5Ns) 용액 50㎎/㎏을 이틀에 한번 씩 일주일간 총 3회 복강 투여하였다. 또한 10, 20, 50, 100㎎/㎏의 담즙희석액도 TAA 투여와 동시에 매일 1회씩 경구투여하였다. 정상대조군의 경우 TAA 투여 및 담즙희석액을 대체할 어떠한 처리도 하지 않았으며, 음성대조군은 TAA 투여 후 담즙희석액과 같은 용량의 멸균생리식염수를 같은 방법으로 투여하였다. Male C57BL / 6 mice aged 7 to 8 weeks were used for the experiment after being purified for 1 week. Six groups including normal control group, negative control group, and four biliary administration groups (10, 20, 50, and 100 mg / kg) prepared in Example 1 were set as experimental groups and 3 to 5 Marie mice were used. To induce liver damage in mice, 50 mg / kg of TAA (thioacetamide, molecular weight: 75.1, chemical formula: C 2 H 5 Ns) solution dissolved in sterilized physiological saline was added to each mouse for one week for one
TAA 및 담즙 투여가 끝나면 호흡마취제로 동물을 마취시키고 개체의 외관 상태를 확인하였다. 이후 복강을 열어 내부 장기 상태를 관찰하였다. After the administration of TAA and bile, the animals were anesthetized with a respiratory anesthetic and their appearance was checked. After the abdominal cavity was opened, the internal organs status was observed.
개체 상태 확인 후 복대동맥에서 혈액을 채취하고 혈청을 분리하여 분석할 때까지 -70℃로 냉동 보관하였다. 간은 상태와 크기를 확인하고 조직 병리학적 진단을 위해 일부는 10% 중성 포르말린에, 나머지는 단백질 분석을 위해 -70℃로 냉동 보관하였다. iochemistry analyzer를 이용하여 하기 표 1과 같은 혈청의 여러 가지 지표들을 분석하였다. Blood samples were taken from the abdominal artery and serum was separated and stored frozen at -70 ° C until analysis. The liver was checked for status and size, and some were frozen in 10% neutral formalin for histopathological diagnosis and the rest were frozen at -70 ° C for protein analysis. iochemistry analyzer was used to analyze various indicators of serum as shown in Table 1 below.
GPT(Glutamate-pyruvate transaminase) GOT (Glutamate-oxaloacetate transaminase)
GPT (Glutamate-pyruvate transaminase)
혈청 지표 증가Liver damage
Increase in serum index
합성Liver protein
synthesis
저하 시 혈청 지표 감소Liver protein synthesis performance
Decrease in serum levels at lowering
2-2. 체중 변화2-2. Weight change
TAA에 의해 간손상이 유도된 마우스의 체중 변화를 6일간의 실험기간 동안 매일 측정하고, 그 결과를 도 1에 나타내었다. 도 1에서 con은 정상대조군을, nc(50)은 음성대조군을, B10은 10㎎/㎏ 담즙투여군을, B20은 20㎎/㎏ 담즙투여군을, B50은 50㎎/㎏ 담즙투여군을, B100은 100㎎/㎏ 담즙투여군을 의미한다. The body weight change of mice induced by liver injury by TAA was measured daily for 6 days, and the results are shown in FIG. In Fig. 1, con was a normal control group, nc (50) was a negative control group, B10 was 10 mg / kg bile administration group, B20 was 20 mg / kg bile administration group, B50 was 50 mg / kg bile administration group, 100 mg / kg biliary group.
도 1에 나타낸 바와 같이, TAA를 투여하지 않은 정상대조군을 제외하고는 투여 2~3일째까지 모든 실험군에서 간 독성으로 인해 체중이 감소하였으며, 그 이후 증가하는 양상을 나타내었다. 특히, 본 발명의 유효성분인 담즙투여군의 경우에는 음성대조군과 대비하여 체중감소율이 비교적 적게 나타남을 확인할 수 있었다. As shown in Fig. 1, except for the normal control group to which TAA was not administered, the body weight decreased due to hepatotoxicity in all the experimental groups from the second to the third administration, and then increased. In particular, in the case of the bile-administered group as the active ingredient of the present invention, it was confirmed that the weight loss rate was relatively low as compared with the negative control group.
실시예Example 3. 혈청 3. Serum GOTGOT (( GlutamateGlutamate -- oxaloacetateoksaloacetate transaminasetransaminase ) 및 GPT(Glutamate-pyruvate ) And GPT (Glutamate-pyruvate transaminasetransaminase ) 분석) analysis
상기 실시예 2에서 간손상 마우스의 혈청의 GOT 및 GPT를 분석하고, 그 결과를 도 2에 나타내었다. 도 2에서 con은 정상대조군을, nc(50)은 음성대조군을, B10은 10㎎/㎏ 담즙투여군을, B20은 20㎎/㎏ 담즙투여군을, B50은 50㎎/㎏ 담즙투여군을, B100은 100㎎/㎏ 담즙투여군을 의미한다. The GOT and GPT of the serum of liver damaged mice were analyzed in Example 2, and the results are shown in FIG. In FIG. 2, con was the normal control group, nc (50) was the negative control group, B10 was 10 mg / kg bile administration group, B20 was 20 mg / kg bile administration group, B50 was 50 mg / kg bile administration group, 100 mg / kg biliary group.
도 2에 나타낸 바와 같이, GOT와 GPT 모두 정상대조군과 비교 시 TAA를 투여한 음성대조군에서 유의성 있게 증가하여 간 손상이 일어났음을 확인할 수 있었다. 또한 GOT 및 GPT 모두 음성대조군과 대비하여 감소하는 경향을 나타냄을 확인할 수 있었다. 특히, GOT의 경우에는 음성대조군과 비교시 10㎎/㎏의 담즙희석액 투여군(B10) 및 20㎎/㎏의 담즙희석액 투여군(B20)에서 유의하게 낮은 결과를 나타내었다. As shown in FIG. 2, the GOT and GPT were significantly increased in the negative control group administered with TAA as compared with the normal control group, indicating that liver injury occurred. In addition, both GOT and GPT showed a tendency to decrease compared with the negative control group. In particular, in the case of GOT, the results were significantly lower in bile diluted group (B10) and 20 mg / kg bile diluted group (B20) than in negative control group.
실시예Example 4. 혈청 TP( 4. Serum TP ( TotalTotal proteinprotein ) 및 ) And ALBALB (( AlbuminAlbumin ) 분석) analysis
상기 실시예 2에서 간손상 마우스의 혈청의 TP 및 ALB를 분석하고, 그 결과를 도 3에 나타내었다. 도 3에서 con은 정상대조군을, nc(50)은 음성대조군을, B10은 10㎎/㎏ 담즙투여군을, B20은 20㎎/㎏ 담즙투여군을, B50은 50㎎/㎏ 담즙투여군을, B100은 100㎎/㎏ 담즙투여군을 의미한다. In Example 2, TP and ALB of serum of liver damaged mice were analyzed, and the results are shown in FIG. In Fig. 3, con was the normal control group, nc (50) was the negative control group, B10 was 10 mg / kg biliary group, B20 was 20 mg / kg biliary group, B50 was 50 mg / 100 mg / kg biliary group.
도 3에 나타낸 바와 같이, 담즙투여군의 경우 음성대조군과 비교하여 담즙 투여량 증가에 따라 혈청의 TP 및 ALB이 유의하게 증가하는 경향을 보였다. As shown in FIG. 3, the serum TP and ALB levels were significantly increased in bile administered group as the bile dose increased as compared with the negative control group.
이상과 같은 결과로부터, TAA 50㎎/㎏을 투여하여 간손상을 유도한 마우스에서 체중의 변화는 3일째까지 체중이 감소하다가 증가하는 양상을 보였으나, 담즙혈청 화학 수치 분석 결과, GOT의 경우 낮은 담즙 농도(B10, B20)에서 음성대조군과 비교 시 수치의 감소를 보여 간 보호 효과를 나타냄을 알 수 있었으며, GPT도 음성대조군과 비교 시 담즙투여군들의 평균값이 감소하는 경향을 보였다. 이 밖에 단백질 합성능 또한 담즙 투여에 따라 높아지는 경향이 나타났다. TP와 ALB 모두 공통적으로 B20, B50군에서 증가하였다. 이상과 같은 결과로부터, 본 발명의 유효성분인 뉴트리아 담즙은 간 손상에 대한 간보호 효과가 있음을 알 수 있었다.From the above results, weight change in the mice induced hepatic injury by administration of 50 mg / kg of TAA showed a decrease in body weight until the third day, but increased in the serum, (B10, B20) compared to the negative control group, indicating a protective effect of the liver. GPT also showed a tendency to decrease in the bile group compared to the negative control group. In addition, protein aggregation performance tended to increase with the administration of bile. Both TP and ALB were increased in B20 and B50 groups. From the above results, it can be seen that the nitalia bile as an active ingredient of the present invention has a liver protective effect against liver injury.
실시예Example 5. 조직 병리 소견 5. Histopathological findings
상기 실시예 2의 TAA 투여 후 멸균생리식염수를 투여한 음성대조군과 10㎎/㎏의 담즙을 투여한 담즙투여군의 마우스를 대상으로 하여 간 조직에 대한 조직 병리학적 진단을 실시하고, 그 결과를 도 8에 나타내었다. After the administration of the TAA of Example 2, the negative control group to which sterilized physiological saline was administered and the bile-administered group of mice to which 10 mg / kg of bile had been administered were subjected to histopathological diagnosis on liver tissues, 8.
도 8에 나타낸 바와 같이, 음성대조군에서는 중심 정맥 주위로 중증도의 간세포 손상 및 염증을 확인할 수 있었으나, 본 발명의 유효성분인 담즙을 투여한 10㎎/㎏의 담즙희석액 투여군(B10)에서는 음성대조군과 대비하여 간세포 손상 및 염증이 감소하였음을 확인할 수 있었다. As shown in FIG. 8, in the negative control group, severe hepatocyte damage and inflammation were observed around the central vein. However, in the group administered with bile (10 mg / kg biliary diluent) (B10) In contrast, hepatocyte injury and inflammation were reduced.
종합적으로, TAA 50㎎/㎏을 투여하여 간손상을 유도한 마우스에서 체중의 변화는 3일째까지 체중이 감소하다가 증가하는 양상을 보였으나, 담즙투여군에서의 체중감소가 음성대조군에 비해 적게 나타나는 양상을 보였다. 혈청 화학 수치 분석 결과에서는, GOT의 경우 낮은 담즙 농도(B10, B20)에서 음성대조군과 비교 시 수치의 감소를 보여 간 보호 효과를 나타냄을 알 수 있었으며, GPT도 음성대조군과 비교 시 담즙투여군들의 평균값이 감소하는 경향을 보였다. 이 밖에 단백질 합성능 또한 담즙 투여에 따라 높아지는 경향이 나타났다. TP와 ALB 모두 공통적으로 B20, B50군에서 증가하였다. 또한 조직병리학적 관찰에서도 염증을 포함한 간세포의 손상성 변화가 적게 나타났다. Overall, weight change in the mice induced hepatic injury by administration of 50 mg / kg of TAA was decreased in body weight until
제제예Formulation example 1. 약학 제제의 제조 1. Manufacture of pharmaceutical preparations
산제Powder 제조 Produce
뉴트리아 담즙 20㎎, 유당 100㎎ 및 탈트 10㎎을 혼합하고 기밀포에 충진하여 산제를 제조하였다.20 mg of nitalia bile, 100 mg of lactose and 10 mg of talt were mixed and filled in an airtight container to prepare a powder.
정제 제조Tablet manufacture
뉴트리아 담즙 10㎎, 옥수수전분 100㎎, 유당 100㎎ 및 스테아린산 마그네슘 2㎎을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.Nutrient bile, 10 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed and tableted according to a conventional preparation method.
캡슐제Capsule 제조 Produce
통상의 캡슐제 제조방법에 따라 뉴트리아 담즙 10㎎, 결정성 셀룰로오스 3㎎, 락토오스 14.8㎎ 및 마그네슘 스테아레이트 0.2㎎을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.10 mg of nitalia bile, 3 mg of crystalline cellulose, 14.8 mg of lactose and 0.2 mg of magnesium stearate were mixed and filled in gelatin capsules according to a conventional capsule preparation method to prepare capsules.
주사제 제조Injection manufacturing
통상의 주사제의 제조방법에 따라 1앰플당(2㎖) 뉴트리아 담즙 10㎎, 만니톨 180㎎, 주사용 멸균 증류수 2,974㎎ 및 Na2HPO4 2H2O 26㎎으로 제조하였다.(2 ml) of Nitric acid bile, 180 mg of mannitol, 2,974 mg of sterile distilled water for injection, and 26 mg of Na 2 HPO 4 2H 2 O according to the usual injection preparation method.
액제Liquid 제조 Produce
통상의 액제의 제조방법에 따라 정제수에 뉴트리아 담즙 20㎎, 이성화당 10g 및 만니톨 5g을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합하였다. 그 다음 정제수를 더 가하여 전체 100㎖로 조절한 후 갈색병에 충진하고 멸균시켜 액제를 제조하였다.20 mg of nitalia bile, 10 g of isomerized sugar and 5 g of mannitol were added to purified water to dissolve the same, and the above ingredients were mixed. Then, purified water was further added thereto, adjusted to a total volume of 100 ml, filled in a brown bottle, and sterilized to prepare a liquid preparation.
제제예Formulation example 2. 식품 제제의 제조 2. Manufacture of food preparation
건강식품 제조Health food manufacturing
뉴트리아 담즙 20㎎, 비타민 혼합물 적량, 비타민 A 아세테이트 70g, 비타민 E 1.0㎎, 비타민 B1 0.13㎎, 비타민 B2 0.15㎎, 비타민 B6 0.5㎎, 비타민 B12 0.2g, 비타민 C 10㎎, 비오틴 10g, 니코틴산아미드 1.7㎎, 엽산 50g, 판토텐산 칼슘 0.5㎎, 무기질 혼합물 적량, 황산제1철 1.75㎎, 산화아연 0.82㎎, 탄산마그네슘 25.3㎎, 제1인산칼륨 15㎎, 제2인산칼슘 55㎎, 구연산칼륨 90㎎, 탄산칼슘 100㎎ 및 염화마그네슘 24.8㎎을 혼합한 다음, 과립을 제조하고 통상의 방법에 따라 건강식품을 제조하였다. 이때, 상기 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하다.Nutria bile, 20 mg of vitamin mixture, 70 g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of vitamin C, 10 g of biotin, 50 mg of folic acid, 0.5 mg of calcium pantothenate, a suitable amount of inorganic mixture, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate monobasic, 55 mg of calcium phosphate dibasic, 100 mg of calcium carbonate and 24.8 mg of magnesium chloride were mixed and granules were prepared and a health food was prepared according to a conventional method. At this time, although the composition ratio of the vitamin and mineral mixture is relatively mixed with the ingredient suitable for health food, it may be arbitrarily modified.
건강음료 제조Health drink manufacturing
통상의 건강음료 제조방법에 따라 뉴트리아 담즙 20㎎, 비타민 C 15g, 비타민 E(분말) 100g, 젖산철 19.75g, 산화아연 3.5g, 니코틴산아미드 3.5g, 비타민 A 0.2g, 비타민 B1 0.25g, 비타민 B2 0.3g 및 정량의 물을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강음료를 제조하였다. 이때, 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.According to the usual method for producing healthy beverages, 20 mg of nitalia bile, 15 g of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, B2 was mixed with a predetermined amount of water, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The resulting solution was filtered and sterilized in a 2 L container to be sterilized by sealing, and then stored in a refrigerator to prepare a health drink. At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand class, demand country, use purpose, and the like.
비록 본 발명이 상기에 언급된 바람직한 실시예로서 설명되었으나, 발명의 요지와 범위로부터 벗어남이 없이 다양한 수정이나 변형을 하는 것이 가능하다. 또한 첨부된 청구 범위는 본 발명의 요지에 속하는 이러한 수정이나 변형을 포함한다.Although the present invention has been described in terms of the preferred embodiments mentioned above, it is possible to make various modifications and variations without departing from the spirit and scope of the invention. It is also to be understood that the appended claims are intended to cover such modifications and changes as fall within the scope of the invention.
Claims (4)
상기 뉴트리아 담즙은 조성물 총 100중량부에 대하여 0.01~95중량부로 포함되는 것을 특징으로 하는 간질환 예방 또는 치료용 약학 조성물.The method according to claim 1,
Wherein the Nitalia bile is contained in an amount of 0.01 to 95 parts by weight based on 100 parts by weight of the total composition.
상기 간질환은 급성간염, 만성간염, 지방간증, 간경화증, 간섬유화증, 간암, 약물에 의한 간염, 황달 및 간경화 중 선택된 어느 하나 이상인 것을 특징으로 하는 간질환 예방 또는 치료용 약학 조성물.The method according to claim 1,
Wherein the liver disease is at least one selected from the group consisting of acute hepatitis, chronic hepatitis, lipid hepatitis, liver cirrhosis, hepatic fibrosis, hepatoma, drug-induced hepatitis, jaundice, and liver cirrhosis.
A food composition for prevention or improvement of liver protection or liver disease comprising nitalia bile as an active ingredient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160117009A KR20180029317A (en) | 2016-09-12 | 2016-09-12 | Composition for preventing, improving or treating liver damage |
PCT/KR2017/009953 WO2018048274A1 (en) | 2016-09-12 | 2017-09-11 | Composition for preventing, alleviating, or treating liver damage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160117009A KR20180029317A (en) | 2016-09-12 | 2016-09-12 | Composition for preventing, improving or treating liver damage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180056494A Division KR101899086B1 (en) | 2018-05-17 | 2018-05-17 | Composition for preventing, improving or treating liver damage |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180029317A true KR20180029317A (en) | 2018-03-21 |
Family
ID=61562177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160117009A KR20180029317A (en) | 2016-09-12 | 2016-09-12 | Composition for preventing, improving or treating liver damage |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20180029317A (en) |
WO (1) | WO2018048274A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003275495A1 (en) * | 2002-11-07 | 2004-06-03 | Walter C. Low | Methods of treating injuries of the nervous system associated with hemorrhage |
EP1871385A1 (en) * | 2005-02-10 | 2008-01-02 | Regents Of The University Of Minnesota | Methods for treating visual disorders |
-
2016
- 2016-09-12 KR KR1020160117009A patent/KR20180029317A/en active Application Filing
-
2017
- 2017-09-11 WO PCT/KR2017/009953 patent/WO2018048274A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018048274A1 (en) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
KR101559130B1 (en) | Composition comprising herbal extract for preventing or treating obesity | |
KR20140137867A (en) | Composition comprising herbal mixture extract for treating or preventing inflammatory disease | |
JP4422685B2 (en) | Use of pinitol or cayloisitol for liver protection | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR101899555B1 (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
KR101899086B1 (en) | Composition for preventing, improving or treating liver damage | |
US10195240B2 (en) | Composition for preventing or treating oxidative brain damage and brain dysfunction, and production method for same | |
KR20160070872A (en) | Composition for prevention or treatment of nonalcoholic fatty liver disease comprising Crataegi Fructus extract | |
KR20150072660A (en) | Hepatoprotective composition containing adenophora triphylla extract | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR20180029317A (en) | Composition for preventing, improving or treating liver damage | |
KR101724587B1 (en) | Composition for treating, improving or preventing liver injury and liver dysfunction | |
KR20120092444A (en) | A composition comprising s for cerebral apoplexy, hypertension, arteriosclerosis and hyperlipidemia, and method for preparation thereof | |
KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR20150105552A (en) | Composition comprising mixture extract of Ephedra sinica, Rheum palmatum L and Arnebia euchroma for preventing or treating obesity | |
KR20200076185A (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and onion | |
KR100610565B1 (en) | Composition comprising mixture of the extract of grape seed and Salicornia herbacea for lowering blood glucose and treating and preventing obesity | |
KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
KR20120073797A (en) | Pharmaceutical composition comprising for preventing and treating an articular rheumatism, extract from the mixture of ponciri fructus, lonicerae flos and angelicae dahuricae radix | |
RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
KR102355441B1 (en) | Composition containing extract of Angelica gigas, extract of Cynanchum wilfordii and extract of Ginko biloba leaves for improving blood circulation | |
US20240261356A1 (en) | Composition containing acanthopanax extract and garcinia cambogia extract or compound isolated therefrom as active ingredient for prevention or treatment of liver disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
A107 | Divisional application of patent |